Vice Chair of Immunology at TSRI joins SAB

9 November 2015

Vice Chairman of Immunology at The Scripps Research Institute to Assist with ValloVax™ Clinical Development Argyrios Theofilopoulos, MD, Joins Batu’s Scientific Advisory Board Batu Biologics, an immuno-oncology company dedicated to the development of its tumor-angiogenesis targeting immune therapy, ValloVax™, announced today the appointment of Argyrios Theofilopoulos, MD of The Scripps Research Institute to its scientific … Continue reading "Vice Chair of Immunology at TSRI joins SAB"....

Read Full Article About Businesswire.com

Batu Recruits Internationally Recognized Immunologist

6 October 2015

Internationally-Recognized Immunologist Joins Batu Biologics’ Quest to Destroy Solid Tumors Francesco Marincola, MD, Joins Batu’s Scientific Advisory Board Batu Biologics, an immuno-oncology company dedicated to the development of its tumor endothelium vaccine, ValloVax™, announced today the appointment of Francesco M. Marincola, MD, FACS, to its scientific advisory board. Read the full article at businesswire.com....

Read Full Article About Businesswire.com

Batu Seeks New Approach to Inhibit Immune Checkpoints

4 September 2015

Batu Biologics Utilizes CRISPR/cas9 Gene Editing to Modify T Cells Immune Checkpoint Silenced T Cells for More Potent, Longer Lasting Anti-Tumor Responses Batu Biologics, an immuno-oncology company, has recently filed intellectual property and initiated discovery research on a new method of augmenting an anti-tumor immune response through ex vivo manipulation of the patient’s T cells. … Continue reading "Batu Seeks New Approach to Inhibit Immune Checkpoints"....

Read Full Article About Businesswire.com

Batu Biologics Completes Seed Round Financing

18 June 2015

Batu Biologics Continues Fight in War Against Lung Cancer Closure of $1 million seed round to support development of anti-angiogenic immune therapy, ValloVax™ Batu Biologics, an immuno-oncology company, has successfully completed its $1 million seed round of funding, bringing the company one step closer in its efforts to battle lung cancer, the leading cancer killer … Continue reading "Batu Biologics Completes Seed Round Financing"....

Read Full Article About Businesswire.com

SD Union Tribune announces Batu’s $1M seed funding

17 June 2015

Batu Biologics has raised $1 million to develop its lung cancer immune therapy, the two-year-old San Diego company said Wednesday. The therapy, ValloVax, is intended to stimulate an immune response against new blood vessels in the lung that tumors use to grow. In preclinical testing, ValloVax inhibited angiogenesis in melanoma, breast and lung cancer mouse … Continue reading "SD Union Tribune announces Batu’s $1M seed funding"....

Read Full Article About Businesswire.com

ValloVax Efficacy Augmented by Checkpoint Inhibitors

15 June 2015

Batu Biologics Reports Combination Therapy Boosts Results in Tumor Blood Vessel-Killing Strategy Company Files Patent on Second Generation Cancer Therapy Batu Biologics, an immuno-oncology company dedicated to the commercialization of its first-in-class tumor blood vessel targeting vaccine, ValloVax, reported today filing of a patent application covering a unique combination therapy of its vaccine together with … Continue reading "ValloVax Efficacy Augmented by Checkpoint Inhibitors"....

Read Full Article About Businesswire.com

Batu Biologics files IP for immune modulator

19 May 2015

Batu Biologics Files Patent on Blood Derived Anti-Cancer Immunomodulator Cancer Angiogenesis Vaccine Company Expands its Therapeutic Pipeline Batu Biologics announced today filing of a patent application covering a recent finding by the company regarding ability to stimulate innate immune system through products that are coaxed out of white blood cells by stimulation with non-toxic agents. … Continue reading "Batu Biologics files IP for immune modulator"....

Read Full Article About Businesswire.com

US Patent Granted for ImmXcyte Technology

23 April 2015

US Patent Granted for Batu Biologics Cancer Immunotherapeutic Product ImmXcyteTM Cancer Angiogenesis Immunology Company Granted Composition of Matter Patent on Universal Immune Stimulatory Peptide Batu Biologics announced the issuance of United States patent # 8,999,349 covering composition of matter claims for its ImmXcyteTM immune-oncology peptide technology. Read the full article at businesswire.com....

Read Full Article About Businesswire.com

Batu Biologics Publishes Preclinical Data for ValloVax™

19 March 2015

Batu Biologics Publishes Preclinical Data for ValloVax™ Company authors peer-reviewed publication about lung cancer immune therapy targeting the tumor endothelium Batu Biologics announced today publication in the Journal of Translational Medicine of the rationale and preclinical data for Batu’s flagship immunotherapeutic product, ValloVax™. Read the full article at businesswire.com....

Read Full Article About Businesswire.com

Batu Biologics Appoints Dr. Santosh Kesari to SAB

4 February 2015

Batu Biologics Appoints Dr. Santosh Kesari to Scientific Advisory Board UC San Diego Moores Cancer Expert to evaluate the clinical potential of ValloVax for Glioblastoma Batu Biologics, an immuno-oncology company based out of San Diego dedicated to the development of its polyvalent tumor endothelium vaccine, ValloVax, announced today the appointment of Santosh Kesari, MD, PhD, … Continue reading "Batu Biologics Appoints Dr. Santosh Kesari to SAB"....

Read Full Article About Businesswire.com
1 2 3 4 5 6